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ABSTRACT
Prostate carcinogenesis involves alterations in several signaling pathways, the 
most prominent being the PI3K/AKT pathway. This pathway is constitutively active 
and drives prostate cancer (PCa) progression to advanced metastatic disease. PTEN, 
a critical tumor and metastasis suppressor gene negatively regulates cell survival, 
proliferation, migration and angiogenesis via the PI3K/Akt pathway. PTEN is mutated, 
downregulated/dysfunctional in many cancers and its dysregulation correlates with 
poor prognosis in PCa. Here, we demonstrate that microRNA-4534 (miR-4534) is 
overexpressed in PCa and show that miR-4534 is hypermethylated in normal tissues 
and cell lines compared to PCa tissues/cells. miR-4534 exerts its oncogenic effects 
partly by downregulating the tumor suppressor PTEN gene. Knockdown of miR-4534 
impaired cell proliferation, migration/invasion and induced G0/G1 cell cycle arrest 
and apoptosis in PCa. Suppression of miR-4534 and its effects on tumor growth 
was confirmed in a xenograft mouse model. We performed parallel experiments in 
non-cancer RWPE1 cells by overexpessing miR-4534 followed by functional assays. 
Overexpression of miR-4534 induced pro-cancerous characteristics in this non-cancer 
cell line. Statistical analyses revealed that miR-4534 has potential to independently 
distinguish malignant from normal tissues and positively correlated with poor overall 
and PSA recurrence free survival. Taken together, our results show that depletion of 
miR-4534 in PCa induces a tumor suppressor phenotype partly through induction of 
PTEN. These results have important implications for identifying and defining the role 
of new PTEN regulators such as microRNAs in prostate tumorigenesis. Understanding 
aberrantly overexpressed miR-4534 and its downregulation of PTEN will provide 
mechanistic insight and therapeutic targets for PCa therapy.
INTRODUCTION
Prostate cancer is the second most prevalent cause 
of cancer deaths among males in the United States [1] 
and the fourth most common tumor type worldwide [2]. 
According to recent data, it is estimated that 220, 800 
newly diagnosed prostate cancer cases and 27, 540 deaths 
will occur in 2015 [1]. The five year relative survival 
rate of early stage prostate cancer is > 99% while that of 
advanced metastatic disease is only 28% [1]. The clinical 
behavior of localized prostate cancer is highly variable, 
while some men have aggressive cancer leading to 
metastasis and death from the disease, many others have 
indolent cancers that are cured with initial therapy or may 
be safely observed. Multiple risk stratification systems 
have been developed, combining the best currently 
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available clinical and pathological parameters (such as 
Gleason score, PSA levels and clinical and pathological 
staging); however, several areas of urgent unmet need 
remain [3–5], e.g., a validated biomarker to complement 
PSA for screening, prognostic biomarkers with clinical 
utility, further risk stratification using molecular 
differentiation could potentially help distinguish indolent 
from aggressive prostate cancer. Prostate carcinogenesis 
features alterations in several signaling pathways, the most 
prominent of which is the highly oncogenic prosurvival 
PI3K/AKT signaling pathway [6]. In human prostate 
cancer, the PI3K/Akt pathway is frequently activated due 
to inactivation of PTEN.
PTEN (phosphatase and tensin homolog deleted 
on chromosome 10; also known as MMAC1 and TEP1) 
is one of the most frequently altered tumor suppressor 
genes in cancer, and in particular, prostate cancer [7, 8]. 
It catalyzes the conversion of the membrane lipid second 
messenger PIP3 to PIP2 and is therefore a key mediator 
of the PI3K/Akt pathway [9]. PTEN levels have been 
identified as being critical in determining the mechanism 
by which prostate tumors evolve in vivo [10, 11]. PTEN 
heterozygosity has been shown to promote tumor 
initiation and proliferation [12]. In addition, primary 
tumors often show loss or alteration of at least one PTEN 
allele in 70%–80% of primary prostate cancers [2, 13], 
while homozygous inactivation of PTEN is generally 
associated with advanced cancer and metastasis [14, 15]. 
Functionally, PTEN is a nonredundant, plasma-membrane 
lipid phosphatase and its inactivation upregulates PI3K/
AKT signaling enhancing protein synthesis, cell migration 
and tumor-induced angiogenesis [16–22]. PTEN has 
been reported to be repressed by oncogenic microRNAs 
(miRNA), e.g., miRNA-21, -214, -301 in many cancers 
[23–26], suggesting that oncogenic activity of these 
miRNAs is in part through downregulation of PTEN. 
Although not much work has been done on oncogenic 
miRNAs as compared to tumor suppressor miRNAs, 
it is very interesting that miRNAs may influence 
carcinogenesis through PTEN regulation.
MicroRNAs (miRNAs) are a naturally-occurring 
class of short, non-coding RNA molecules between 19 and 
21 nucleotides long [27]. In humans approximately 2,8645 
unique mature miRNAs have been identified (http://www. 
http://mirdb.org/miRDB/). While the exact function of 
miRNAs remain to be fully elucidated, they are known 
to regulate gene expression via binding target messenger 
RNA (mRNA), inhibiting translation or triggering mRNA 
degradation. Importantly, it has been demonstrated that 
in addition to their inhibitory role, miRNAs can also 
induce or activate transcript levels [28–30]. Through 
these mechanisms miRNAs perform a regulatory role in 
various cellular processes, including cell development, 
differentiation, proliferation and apoptosis [29, 31, 32]. 
Dysregulated miRNA expression patterns have been 
noted in many organisms, encompassing a wide spectrum 
of pathological processes, from immunological defects in 
fish, altered developmental phase transition and flowering 
time in plants, and neurodegeneration, cardiovascular 
disease and cancer in humans [33, 34]. Discovery of 
dysregulated miRNA expression has led to the hypothesis 
that miRNAs could potentially be used as disease 
diagnostic or prognostic markers. Furthermore, miRNA 
are attractive therapeutic targets for the treatment of 
various conditions, including cancer. At present, multiple 
clinical trials are currently registered with ClinicalTrials.
gov, investigating the ability of miRNA to function as 
disease biomarkers and response to current therapies. 
The novel role of miRNA and their importance in many 
different processes has led to an explosion of scientific 
enquiry into miRNA function. Thus the aim of this study 
is to understand the role of microRNA-4534 (miR-4534) 
dysregulation in promoting prostate oncogenesis. miR-
4534 was selected based on our previous study [35] 
that we performed to preliminary screen and identify 
differentially expressed miRNAs in prostate cancer cell 
lines compared to a non-malignant cell line.  A set of 
miRNAs, miR-205, -203, 23b and -34b were found to 
be significantly downregulated whereas miR-4534 was 
significantly upregulated in prostate cancer cells compared 
to a non-malignant cell line.
In this study we report that: (i) miR-4534 is 
overexpressed in prostate cancer tissues and cell lines 
compared to matched normal samples and cell lines; (ii) 
miR-4534 has potential to distinguish malignant from 
normal tissues; (iii) miR-4534 functions as an oncomiR 
as its attenuation results in cell cycle arrest, apoptosis, 
impaired migration/invasion and colony forming 
capability of prostate cancer cells; (iv) miR-4534 directly 
targets PTEN and its downstream effectors to exert its 
functional effects; (v) intra-tumoral delivery of anti-
miR-4534 (anti4534) inhibits in-vivo tumor growth in 
nude mice xenografts.
RESULTS
miR-4534 upregulation is correlated with 
methylation status in prostate cancer 
In a previous study [35], we performed preliminary 
screening to identify differentially expressed miRNAs in 
prostate cancer cell lines compared to a non-malignant 
cell line.  A set of miRNAs, miR-205, -203, 23b and -34b 
were found to be significantly downregulated whereas 
miR-4534 was significantly upregulated in prostate cancer 
cells compared to a non-malignant cell line. We validated 
this data by miRNA-quantitative real time PCR (miR 
qRT-PCR) analysis. The results confirmed that miR-4534 
was overexpressed in prostate cancer cell lines compared 
to normal RWPE1 cells (Figure 1A). Further, miR-4534 
expression was analyzed in 168 (84 pairs) of laser-
captured micro-dissected (LCM) matched clinical samples 
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(Figure 1B), an unmatched group of 14 benign prostatic 
hyperplasia (BPH) and 14 tumor samples (Figure 1C). 
Among all tissues miR-4534 expression was significantly 
upregulated in cancer samples compared to normal or 
BPH tissues (Figure 1A–1C). These results indicate a 
putative oncogenic role for miR-4534 in prostate cancer.   
Bert et al. [36] published an interesting study in 
“Cancer Cell” in which they report that extensive DNA 
hypermethylation of CpG islands is strongly related to 
cancer-specific gene activation. Guided by this study, we 
were curious to know the methylation status of miR-4534 
in normal and prostate cancer and identified a CpG island 
in the upstream 1kb sequence of miR-4534 (Figure 1D). 
Interestingly, we observed hypermethylation of miR-4534 
in a normal cell line compared to the Du145 cancer cell 
line (Figure 1E). We also examined the methylation status 
in several tissue samples and the results were consistent 
with hypermethylation observed in normal samples 
compared to their matched cancers (Figure 1F). Since our 
group has been working on the effect of genistein-a natural 
chemotherapeutic agent on various cancer cells, we also 
looked at the effect of genistein on prostate cancer cells 
and observed that genistein treatment of Du145 cancer 
cells suppressed miR-4534 expression levels (Figure 1G). 
Thus the methylation status is in agreement with the 
expression profile of miR-4534 in normal and prostate 
cancer cells and tissues.
Clinical significance of miR-4534 in prostate 
cancer
Clinical demographics of the study cohort are 
summarized in Supplementary Table S1. Receiver 
operating curve (ROC) analyses were performed to 
evaluate the ability of miR-4534 expression to discriminate 
between normal and tumor cases. An area under the 
ROC curve (AUC) of 0.9 (P <0.0001; 95% CI = 0.834 
to 0.946) (Figure 2A) was obtained suggesting that miR-
4534 expression can discriminate between malignant and 
non-malignant samples and hence has potential to be 
used as a diagnostic marker for PCa, though it needs to 
be validated in a larger independent cohort. To determine 
whether miR-4534 has prognostic significance, we divided 
84 cases into low miR-4534 (expression T/N < 0.8 fold) 
and high miR-4534 (expression T/N > 0.8 fold) groups 
and performed Kaplan-Meier survival analysis. The 
results show that the low miR-4534 group displayed 
significantly higher overall survival probability compared 
to the high miR-4534 group (Logrank Test p < 0.04, 
HR = 6, 95% CI = 3–17) (Figure 2B). Kaplan-Meier 
survival analysis for recurrence free survival was 
performed for the same sample cohort and cases with low 
miR-4534 expression had better recurrence free survival 
than with high miR-4534 expression cases (Logrank Test 
p < 0.01, HR = 5, 95% CI = 3–10) (Figure 2C). We also 
determined the correlation of miR-4534 expression with 
clinicopathological variables such as Gleason grade, 
pathological stage (pT), biochemical recurrence and 
survival (Figure 2D). Correlation tests revealed that cases 
with high miR-4534 expression increased from low grade, 
low pathological stage to high grade and high pathological 
stage (Figure 2D). Patients that had PSA recurrence also 
had significantly high miR-4534 expression. 
Attenuation of miR-4534 impairs cell 
proliferation and induces cell cycle arrest and 
apoptosis in prostate cancer
To determine the functional significance of miR-
4534 in prostate cancer, we transfected prostate cancer 
cell lines with miR-4534 inhibitor (anti4534; 50 nM) 
(Figure 3A) or a control inhibitor for 72 or 96 hours 
as indicated followed by functional assays. Transient 
transfection of cells with anti4534 resulted in significantly 
decreased cell proliferation over time (Figure 3B) as 
compared to cells expressing anti-control-miR sequence 
(control). We further examined the effects of anti4534 
on prostate cancer cell viability using a colony formation 
assay. The anti4534-transfected cells showed low colony 
formation ability, as both the size and number of foci in 
anti4534 expressing cells was suppressed when compared 
to control expressing cells (Figure 3C). Cell cycle analysis 
revealed a significant increase in G0/G1 cell population 
(9–10%) with a concomitant decrease in the S-phase 
(8–11%) of prostate cancer cells transfected with anti4534 
compared to control (Figure 4A–4B). Repression of 
miR-4534 also induced apoptosis in cancer cells as 
compared to control (8–14%) (Figure 4C–4E). These results 
confirm the phenotypic effects of miR-4534 downregulation 
in human prostate cancer cells.
Knockdown of miR-4534 suppresses prostate 
cancer cell migration and invasion 
Transient transfection of Du145 cells with anti4534 
resulted in a significant decrease in migration (40%, 
p < 0.0001) and invasion (50%, p < 0.0001) post 72 h 
transfection (Figure 5A–5C) and the results were 
consistent with the MDAPCa2b cancer cell line with a 
decrease in migration (60%, p < 0.0001) and invasion 
(70%, p <0.0001) after 96 h transfection (Figure 5D–5F) 
compared to control cells. These findings suggest that loss 
of miR-4534 expression impairs migration and invasion of 
prostate cancer cell lines. 
miR-4534 directly represses the tumor 
suppressor PTEN gene and its down-stream 
effectors involved in proliferation/survival/
invasion and migration pathways 
Based on the phenotypic effects of miR-4534 depletion, 
we focused on the putative gene targets of miR-4534 
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in prostate cancer. We utilized in silico computational 
algorithms (miRbase.org) and identified complimentary 
binding sites in the 3ʹUTR of PTEN (Figure 6A), a 
master negative regulator of the pro-survival PI3K/Akt 
pathway. Western analysis showed that downregulation 
of miR-4534 attenuated PTEN protein expression 
in three prostate cancer cell lines (Figure 6B–6D). 
To validate if miR-4534 directly targets PTEN, we 
performed 3ʹUTR luciferase reporter assays with the three 
cell lines (Figure 1F–1H). Co-transfection of the indicated 
concentrations of miR-4534 along with wild type 3ʹUTR 
of PTEN significantly repressed relative luciferase activity 
(Figure 1F–1H), whereas no effect was observed with 
cont-miR or miR-4534 transfected with a mutated PTEN 
3ʹUTR, suggesting that miR-4534 directly targets the wild 
type 3ʹUTR of the PTEN tumor suppressor gene. Next we 
determined the effect of miR-4534 mediated suppression of 
PTEN on the downstream pathway genes. Results indicated 
that induction of PTEN by knockdown of miR-4534 resulted 
in the upregulation of p53, p73, and p21 protein that are 
involved in prostate cancer cell growth and progression. 
Depletion in posphoAkt levels was also observed, a 
critical molecule in tumor development, cell survival and 
proliferation (Figure 6I–6J). These results support our 
hypothesis that miR-4534 is an onco-miR that exerts its 
phenotypic effects partly through PTEN and the downstream 
PI3K/Akt pathway in prostate cancer.
Overexpression of miR-4534 causes pro-cancerous 
properties in non-cancerous RWPE1 cells
To determine the biological significance of miR-4534 
in prostate cancer, we performed parallel experiments 
in the non-cancerous RWPE1 cell line. miR-4534 was 
Figure 1: miR-4534 expression and methylation status in prostate cancer. (A) Quantitative RT-PCR analysis of miR-4534 in 
cell lines. (B–C) Quantitative real time PCR analysis of mir-4534 expression in 84 pairs of matched Laser-Captured Microdissected tissue 
samples (B) and non-matched BPH and cancer cohort (C). (D) CpG island within the 1.0 kb region upstream of miR-4534 gene. Sequences 
of methylation primers and probes are given in Supplementary Table S2. (E–F) Mir-4534 methylation percentage in Du145 prostate cancer 
cell line compared to non-cancer RPWEI cells (E) and matched tissue samples  (F). (G) Negative regulation of mir-4534 expression by 
genistein treatment in Du145 cell line. 
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over-expressed in RWPE1 cells by transient transfection 
of  miR-4534 mimic (premiR-4534; 50 nM) along with a 
negative-miRNA-control (control) (Figure 7A). RWPE1 
cells transfected with premiR-4534 showed a considerable 
increase in proliferation (Figure 7B) compared to control. 
Moreover, there was an increase in the S-phase of the 
cell cycle including enhanced migration, invasion and 
colony formation capability of cells transfected with 
pre-miR-4534 compared to control (Figure 7C–7I). These 
data provide evidence that overexpression of miR-4534 
caused RWPE1 cells to have cancer like characteristics. 
We further determined the effect of overexpression of 
miR-4534 on PTEN and Akt by qRT-PCR. As expected 
there was a decrease in relative expression of PTEN with 
an increase in Akt1-3 relative expression. GAPDH was 
used as an endogenous control. 
Intra-tumoral delivery of anti4534 suppresses 
tumorigenecity in vivo
We also performed in-vivo growth suppression 
experiments to determine the tumor suppressive effect of 
miR-4534 depletion by local administration of anti4534 
or control in established tumors. Tumor growth was 
significantly suppressed by anti4534 over the course of 
the experiment compared to controls. Average tumor 
volume in controls was 132 mm3 compared to the average 
tumor volume of 74 mm3 in mice that received anti4534 
(Figure 8) at the termination of the experiment. These 
results confirm the in vitro tumor suppressive effect of 
downregulation of miR-4534 in a prostate xenograft 
model.  
DISCUSSION
miR-4534 is located at Chromosome22q13.1 
(Chr22q13.1). The loci Chr22q13 and Chr22q12.3-q13.1 
have been reported to be associated with prostate cancer 
aggressiveness [37, 38]. Very little is known about 
miR-4534 and a pub-Med search resulted in one 
publication that was performed in Type 2 diabetes [39]. 
We also utilized online publicly available data bases to 
look for any information about miR-4534. We found 
that miR-4534 was shown to be amplified in 2% of 
tumor samples in the Prostate Adenocarcinoma (Nelson 
Lab, Fred Hutchinson CRC) sample cohort (http://www.
cbioportal.org/). While the online data base “The European 
Bioinfomatics Institute” (EBI; http://www.ebi.ac.uk/) 
shows that the expression of miR-4534 is less in normal 
prostate. In our preliminary screening analysis, we found 
Figure 2: Clinical significance of miR-4534 in prostate cancer. (A) ROC curve analysis showing performance of miR-4534 
expression to discriminate between malignant and non-malignant tissue samples. (B–C) Kaplan-Meier analysis for overall survival and 
recurrence free survival based on miR-4534 expression. (D) Chi-square test showing correlation of clinicopathological characteristics with 
miR-4534 expression. 
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miR-4534 to be upregulated in cancer cells compared 
to normal RWPE1 cells. We confirmed overexpression 
of miR-4534 in laser-captured micro-dissected prostate 
cancer clinical samples and cancer cell lines compared 
to matched normal tissues and a non-cancerous cell line 
(RWPE1) by quantitative-real-time-PCR (qRT-PCR). Thus 
our data is consistent with the EBI report that miR-4534 
is low in normal prostate tissues compared to matched 
cancer tissues. However, to the best of our knowledge no 
study has been performed on the status and functional role 
of this novel miRNA in cancer.
Our results reveal that miR-4534 expression 
has clinical significance in prostate cancer as it can 
independently differentiate malignant from normal 
tissues. Higher miR-4534 expression positively correlated 
with poor overall and recurrence free survival. From a 
clinical point of view, miRNAs possess several features 
that make them attractive candidates as new diagnostic 
and prognostic biomarkers of cancer [40] and miRNA 
signatures have been reported to be useful tools for early 
diagnosis of cancer [41, 42]. In this study, we found that 
miR-4534 has potential to be a diagnostic biomarker for 
prostate cancer and for predicting biochemical relapse 
(p < 0.01) in patients. These results need to be confirmed 
in a larger independent cohort of patient samples.
We found that miR-4534 impaired cell viability and 
proliferation of prostate cancer cells and G0/G1 cell cycle 
arrest was observed with the induction of apoptosis. In 
addition, a decrease in cell migration and invasion was noted 
after transient transfection of anti4534 in prostate cancer 
cells. These results confirm the oncogenic role of miR-4534 
as its depletion caused tumor suppression in prostate 
cancer cells. miRNAs being non-coding RNAs exert their 
functional effects by regulating gene expression via binding 
target messenger RNA (mRNA) and inhibiting its translation 
or triggering mRNA degradation [28, 31, 32]. We utilized in-
silico algorithms to find miR-4534 target genes in the PI3K/
Akt survival pathway and found that PTEN has miR-4534 
binding sequence in its 3ʹUTR. Immunoblot assay showed 
significant upregulation of PTEN protein after repression 
of miR-4534 in prostate cancer cells. Luciferase reporter 
assays with three prostate cancer cell lines confirmed that 
miR-4534 directly targets the PTEN gene. Hence this study 
shows that miR-4534 exerts its oncogenic effects partly 
Figure 3: Effect of miR-4534 knockdown in prostate cancer cells. (A) Expression of miR-4534 post transient transfection 
of 50 nM miR-4534 inhibitor (anti4534) in prostate cancer cells compared to anti-miR-control inhibitor (control). (B) Proliferation of 
MDAPCa2b and Du145 cells. After anti4534 transfection cell proliferation was significantly reduced compared to control. (C) miR-4534 
depletion significantly inhibits prostate cancer cell colony formation. 
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by downregulating the tumor suppressor PTEN gene. It is 
possible that miR-4534 might also target additional target 
genes since a single miRNA can target a broad range 
of molecular regulators in a context-dependent manner. 
Functional loss of PTEN leads to aberrant activation of 
the oncogenic PI3K/Akt pathway and is instrumental in 
promoting cancer development, progression and metastasis 
[16, 43–48]. Thus, restoration of PTEN function represents 
a major therapeutic strategy for the management of prostate 
cancer (Figure 9). We found that depletion of miR-4534 
caused an induction in PTEN expression that resulted in 
G0/G1cell cycle arrest and increased apoptosis with 
inhibition of migration and invasion in prostate cancer cells. 
In addition, anti4534 mediated induction of PTEN decreased 
downstream pAkt and induced p21, p53 and p73 that are 
involved in cell survival, apoptosis, proliferation, growth, 
migration and angiogenesis [16, 17, 49–58]. This study 
reveals that miR-4534 promotes the oncogenic PI3K/Akt 
module by inhibiting the PTEN gene in prostate cancer. The 
PTEN/PI3K/Akt pathway is amenable to pharmacological 
manipulation, and PTEN itself may become a drug target 
as is the case for p53 [16, 59, 60]. The discovery of new 
regulators, such as miRNAs that influence PTEN expression 
and a greater understanding of their regulatory networks will 
assist in employing the bonafide tumor suppressor PTEN 
gene to inhibit prostate tumorigenesis.  
We also examined the biological significance of 
miR-4534 in a non-cancerous prostate cell line (RWPE1) 
and found that overexpression of miR-4535 induces pro-
cancerous characteristics highlighting the importance of 
this miRNA in the oncogenesis of prostate cancer. The anti-
tumorigenic effects of depletion of miR-4534 observed in 
this study were also confirmed in a PCa xenograft nude 
mouse model. In vivo experiments demonstrated a striking 
suppression in subcutaneous tumor growth in nude mice 
where anti4534 was directly administered to tumors. 
Therefore, our study demonstrates that targeting this novel 
oncogenic miR-4534 inhibits prostate cancer growth and 
progression both in vitro and in vivo. 
In summary, our study has identified novel 
oncogenic miR-4534 harbored at locus Chr22q13.1 that 
is implicated in aggressive prostate cancer. miR-4534 
expression has clinical significance to be a diagnostic/
prognostic biomarker as it can diagnose prostate cancer 
from normal tissues and is positively correlated with 
poor overall and recurrence free survival. We also found 
Figure 4: Knockdown of miR-4534 induces G0/G1 cell cycle arrest and apoptosis in prostate cancer cells. (A–B) Cell 
cycle analysis showing an increase in the G0/G1 phase of Du145 and MDAPCa2b cells after transfection with anti4534. (C–E) Apoptosis 
assay showing induction of apoptosis by anti4534. *p < 0.05, ± CI.
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that miR-4534 is overexpressed in prostate cancer and 
directly targets PTEN leading to its downregulation. 
Furthermore, induction of PTEN could be achieved by 
miR-4534 depletion, which caused significant inhibition 
of tumorigenesis in prostate cancer cells. We conclude that 
therapeutic modulation of miR-4534 in prostate tumors 
provides an alternative option for the management of 
prostate cancer.
MATERIALS AND METHODS
Cell culture, plasmids and probes/primers
Human prostate cancer cell lines MDAPCa2b, 
Du145 and a non-malignant prostate cell line RWPE1 
were obtained from the American Type Culture Collection 
(ATCC) (Manassas, VA) and grown according to 
ATCC protocol. These human-derived cell lines were 
authenticated by DNA short-tandem repeat analysis by the 
ATCC. TaqMan probes for hsa-miR-4534, negative control 
pre-miR, inhibitor of miR-4534 and anti-control inhibitor 
(control) were purchased from Applied Biosystems (Foster 
City, CA). For luciferase reporter assays, pMIR-REPORT 
luciferase vector was purchased from Ambion, Cambridge 
MA. Genistein was purchased from Sigma (Sigma, St. 
Louis, MO) and dissolved in DMSO. Genistein treatment 
was performed as described previously [61]. Briefly, 
subconfluent cells (60–70% confluent) were treated with 
varying concentrations of  25 and 50 umol/L genistein and 
cells treated with vehicle (DMSO) served as control. The 
cells were treated with fresh genistein along with change 
of media and grown for 3 days. 
Figure 5: Knockdown of miR-4534 inhibits migration and invasion in prostate cancer cells. (A–C) Migration and invasion 
assays in Du145 cells transfected with anti4534 compared to anti-negative control miR (control). (D–F) A significant decrease in the 
percent migrating or invading MDAPCa2b cells was observed with anti4534 compared to control.
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Quantitative real-time PCR
Tissue samples from radical prostectomy were 
obtained from the Veterans Affairs Medical Center, 
San Francisco, CA, USA. Total RNA was extracted 
and assayed for mature miRNAs and mRNAs using the 
TaqMan MicroRNA Assays and Gene Expression Assays, 
respectively, in accordance with the manufacturer’s 
instructions (Applied Biosystems). All RT reactions 
were run in a 7500 Fast Real Time PCR System (Applied 
Biosystems). Relative expression was calculated using the 
comparative Ct.
Methylation analysis of miR-4534 by 
quantitative methylation-specific PCR (qMSP)
To investigate the methylation status of miR-4534 
in PCa we performed methylation analysis in in cell lines 
and tissue samples. DNA was bisulfite converted using 
EZ DNA Methylation-Gold Kit (Zymo Research, Orange, 
CA, USA) according to the manufacturer’s protocol. The 
converted DNA was amplified by PCR with 400 pM of 
primer set F1/R1, and HotStar Taq Plus DNA Polymerase 
(Qiagen, Valencia, CA, USA). PCR was performed by 
denaturation at 95°C for 5 minutes, followed by 15 cycles 
of 94°C for 30 seconds, 56°C for 30 seconds and 72°C for 
30 seconds. 2 µl of the PCR product was added to 40 µl 
solution containing 20 µl TaqMan Fast Universal PCR 
Master Mix (2×) (Applied Biosystems), 500 pM primers 
F1/R1. The mixed solution was aliquoted evenly into two 
tubes, and was added 1 µl 5 µM probe for methylation 
reaction (PM) for Methylation (M) reaction and 1 µl 
5 µM probe for unmethylation reaction (PU) probe for 
Unmethylation (U) reaction, respectively. Methylation was 
measured by realtime quantitative PCR with an Applied 
Biosystems 7500 Fast Sequence Detection. For each 
sample, the percent of methylation was calculated by the 
difference of Ct in M reaction (Ct-M) and Ct in U reaction 
(Ct-U). The probes for methylation/unmethylation specific 
realtime PCR were synthesized by Applied Biosystems 
(Foster City, CA, USA), labeled with 6FAM reporter at 5ʹ 
end and with MGB quencher at 3ʹ end. The sequences of 
primers and probes are given in Supplementary Table S2.
Figure 6: miR-4534 directly targets tumor suppressor PTEN and regulates downstream pathway genes involved in 
cell proliferation, survival and migration.  (A) Complimentary binding site for miR-4534 in 3ʹUTR of PTEN gene. (B–E) Transient 
transfection of anti4534 caused a significant increase in PTEN protein levels compared to control. (F–H) Luciferase assays showing 
decreased reporter activity after co-transfection of either wild type PTEN-3ʹUTR or its mutated 3ʹUTR with miR-4534 in prostate cancer 
cells. (I–J) Western blot analysis showing decreased expression of PTEN downstream genes involved in the survival pathway. 
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Figure 7: Overexpression of miR-4534 in normal prostate cells (RWPE1). (A) miR-4534 expression after transient transfection 
of pre-miR-4534 compared to pre-miR-negative control (control). (B) miR-4534 overexpression in normal prostate cells induced cell 
proliferation. (C–I) An increase in the s-phase cell population (C–D) along with increased migration (E–F), invasion (G–H) and colony 
formation (I) capability of RPWE1 cells after overexpression of miR-4534 mimic. (J) Relative mRNA expression of PTEN, Akt1-3 in 
miR-4534 overexpressing RWPE1 cells compared to control. GAPDH was used as an endogenous control. 
Figure 8: Inhibition of in vivo tumor growth by intratumoral injection of anti4534. *p < 0.05 (A) Tumor volume following 
intratumoral injection of control or anti4534 into established tumors. Data represents the mean of each group and error bars are S.E.M. 
(B) Representative pictures of mice injected with either control or miR-4534 at the termination of experiment. 
Oncotarget68381www.impactjournals.com/oncotarget
Flow cytometry, cell viability, migration, 
clonability and invasion assays
FACS analysis for cell cycle and apoptosis was 
done 72 hours (96 hrs for MDAPCab cells) post-
transfection using nuclear stain DAPI for cell cycle 
analysis or ANNEXIN V-FITC /PI KIT (Betkin Dikeson) 
for apoptosis analysis according to the manufacturer’s 
protocol. Cell viability was determined at 24, 48, 72 and 
96 h by using the CellTiter 96 AQueous One Solution Cell 
Proliferation Assay kit (Promega, Madison, WI) according 
to the manufacturer’s protocol. For colony formation 
assay, cells were seeded at low density (1000 cells/plate) 
and allowed to grow until visible colonies appeared. Then, 
cells were stained with Giemsa and colonies were counted. 
Cytoselect 24-well cell migration and invasion assay kit 
(Cell Biolabs, Inc) was used for migration and invasion 
assays according to manufacturer’s protocol. 
Immunoblotting 
Immunoblotting was performed as described 
previously [30]. The antibodies used were specific for 
Akt (4685; Cell Signaling), p-Akt(Ser473) (4060; Cell 
Signaling), PTEN (9552; Cell Signaling), P53 (2524; 
Cell Signaling), P73 (14620; Cell Signaling), p21 
(2947; Cell Signaling) and GAPDH (sc-32233; Santa 
Cruz Biotechnology, Inc.). Blots were visualized using 
Western blotting luminal reagent (sc-2048; Santa Cruz 
Biotechnology, Inc.). 
Luciferase assays
The complimentary sites in 3ʹUTR of PTEN for miR-
4534 and mutated sequences are given in Supplemental 
Table. The 3ʹ-UTR region of PTEN containing target site 
sequences complementary to the seed sequence of miR-
4534 were cloned downstream of the luciferase gene in 
the pMIR-REPORT luciferase vector (Ambion, Cambridge 
MA), and the resultant vectors named PTEN-3ʹUTR. 
Mutated 3ʹUTR sequences of PTEN complementary 
to miR-4534 were cloned in the same vector and the 
resultant vectors named PTEN-Mut 3ʹUTR. For reporter 
assays, cells were transiently transfected with wild-type or 
mutated reporter plasmid and miR-4534 or control-miR. 
Firefly luciferase activities were measured using the Dual 
Luciferase Assay (Promega, Madison, WI) 24 hr after 
transfection and the results were normalized with Renilla 
luciferase. Each reporter plasmid was transfected at least 
three times and each sample was assayed in triplicate.
Figure 9: Schematic representation of role of miR-4534 in prostate cancer. Inhibition of miR-4534 leads to induction of PTEN 
that leads to inhibition of PI3K/Akt pathway causing inhibition of growth, survival, proliferation and migration of prostate cancer cells. 
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In vivo intratumoral delivery of anti4534 
The antitumor effect of depletion of miR-4534 
was determined by local administration of miR-4534 
miRVANA miRNA inhibitor (antimiR) in established 
tumors in athymic nude mice and compared to antimiR-
negative control mice group. Each mouse was injected 
sub-cutaneously with 2.0 × 106 Du145 prostate cancer cells. 
Once palpable tumors developed, 6.25 µg of synthetic 
anti4534 or antimiR-negative control (control) complexed 
with 1.6 µl siPORT Amine transfection reagent (Ambion, 
Austin, TX) in 50 µl PBS was delivered eight times 
intratumorally at 3-day intervals. In total 8 mice received 
anti4534 and 8 mice received control miR. Tumor growth 
was followed for 21 days from the first injection. All animal 
care was in accordance with the institutional guidelines. 
Statistical analysis
Statistical analyses were performed with StatView 
for Windows (SAS Institute Inc. NC, USA), GraphPad-
Pris- 5 and MedCalc. All quantified data represents 
average of at least triplicate samples and three experiments 
performed at different times or as indicated. Error bars 
represent standard deviation of mean or as indicated. All 
tests were performed two tailed and p-values < 0.05 were 
considered statistically significant. Receiver operating 
curves (ROC) were calculated to determine potential of 
miR-4534 to discriminate between malignant and non-
malignant samples. Chi-square tests were performed to 
determine correlation between miR-4534 expression and 
clinicopathological characteristics.
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